KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Debt (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Total Debt for 6 consecutive years, with $10.1 million as the latest value for Q4 2025.

  • Quarterly Total Debt changed 0.34% to $10.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.1 million through Dec 2025, changed 0.34% year-over-year, with the annual reading at $10.1 million for FY2025, 0.34% changed from the prior year.
  • Total Debt hit $10.1 million in Q4 2025 for Castle Biosciences, roughly flat from $10.0 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $20.8 million in Q1 2022 to a low of $10.0 million in Q1 2024.
  • Historically, Total Debt has averaged $11.2 million across 3 years, with a median of $10.0 million in 2025.
  • Biggest YoY gain for Total Debt was 0.34% in 2025; the steepest drop was 0.32% in 2025.
  • Year by year, Total Debt stood at $20.8 million in 2022, then tumbled by 51.93% to $10.0 million in 2024, then rose by 0.34% to $10.1 million in 2025.
  • Business Quant data shows Total Debt for CSTL at $10.1 million in Q4 2025, $10.0 million in Q3 2025, and $10.0 million in Q2 2025.